BMS posts long-term SAR302503 myelofibrosis results; launches Phase III lung cancer trial

Bristol-Myers Squibb had three registry updates during the week, led by newly posted long-term results in myelofibrosis and a newly listed Phase III lung cancer study.

• An open-label extension study of orally administered SAR302503, also called TG101348, in patients with primary or secondary myelofibrosis is listed as completed, with actual primary and study completion dated 2014-05-28. The trial enrolled 43 participants¹ and evaluated the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who had completed the MF-TG101348-001 study¹. Posted results for best overall response per IWG-MRT criteria showed participant counts of 1, 0, 31, 11, and 0 across response categories, with serious adverse events reported in 23 of 43 participants¹.
• A new Phase III trial, "IZABRIGHT-Lung02," is recruiting to compare izalontamab brengitecan (BMS-986507) plus osimertinib against osimertinib alone or osimertinib plus platinum-based chemotherapy as first-line therapy in EGFR-mutant non-small cell lung cancer. The study has an estimated enrollment of 850 participants² and actual start date of 2026-09-08, with primary and study completion estimated for 2031-12-30².
• The Phase 1 study of navlimetostat (BMS-986504) drug interactions and food effect in healthy female participants remains listed as recruiting. The trial has an estimated enrollment of 80 participants³ and estimated primary and study completion of 2027-03-25³.